BIO-TECHNE CORP shareholders Q3 2023

BIO-TECHNE CORP's ticker is TECH and the CUSIP is 09073M104. A total of 517 filers reported holding BIO-TECHNE CORP in Q3 2023. The put-call ratio across all filers is 0.43 and the average weighting 0.2%.

BIO-TECHNE CORP shareholders Q3 2023
NameSharesValueWeighting ↓
Asset Management One Co., Ltd. 119,611$8,140,6290.04%
TRAN CAPITAL MANAGEMENT, L.P. 4,000$272,2800.04%
ExodusPoint Capital Management, LP 54,217$3,6910.04%
XPONANCE, INC. 37,524$2,554,2590.04%
NISA INVESTMENT ADVISORS, LLC 67,786$4,614,1930.04%
First Trust Direct Indexing L.P. 4,380$298,1490.03%
Invesco Ltd. 1,880,812$128,026,8720.03%
Accredited Investors Inc. 6,421$437,1000.03%
WELLINGTON MANAGEMENT GROUP LLP 2,395,379$163,053,4490.03%
AMALGAMATED BANK 57,175$3,8920.03%
Diversified Trust Co 12,826$873,0650.03%
Graham Capital Management, L.P. 19,901$1,354,6610.03%
BLAIR WILLIAM & CO/IL 120,833$8,225,1320.03%
Proficio Capital Partners LLC 3,511$238,9960.03%
Kentucky Retirement Systems 12,983$883,7530.03%
COMERICA BANK 86,931$5,917,3720.03%
STATE BOARD OF ADMINISTRATION OF FLORIDA RETIREMENT SYSTEM 192,576$13,108,6490.03%
Kentucky Retirement Systems Insurance Trust Fund 5,797$394,6020.03%
TWO SIGMA ADVISERS, LP 174,968$11,910,0720.03%
VANGUARD GROUP INC 18,354,669$1,249,402,3190.03%
About BIO-TECHNE CORP

Bio-Techne Corp is a leading provider of innovative life science research tools and diagnostic solutions. The company is headquartered in Minneapolis, Minnesota, and has operations in over 50 countries worldwide. Bio-Techne's products and services are used by researchers and clinicians in a wide range of fields, including cancer research, stem cell research, and immunology.

Bio-Techne's success is due in large part to its commitment to innovation and customer service. The company invests heavily in research and development, and has a team of over 1,000 scientists working to develop new products and technologies. Bio-Techne also has a strong focus on customer service, with a dedicated team of technical support specialists available to assist customers with any questions or issues they may have.

In addition to its research tools and diagnostic solutions, Bio-Techne also has a growing portfolio of clinical diagnostic products. The company's Exosome Diagnostics subsidiary is a leader in the development of liquid biopsy tests for cancer diagnosis and monitoring.

Bio-Techne's leadership team is comprised of experienced executives with a track record of success in the life sciences industry. Charles Kummeth, the company's CEO, has been with Bio-Techne since 2013 and has overseen significant growth and expansion during his tenure.

Overall, Bio-Techne is a company with a strong reputation for innovation, customer service, and leadership in the life sciences industry. With a growing portfolio of products and services, the company is well-positioned for continued success in the years to come.

It's important to note that this information is for educational purposes only and has not been fact-checked. As with any investment, it's important to do your own research and consult with a financial advisor before making any investment decisions.

External links

This page lists BIO-TECHNE CORP's shareholders in Q3 2023. To view BIO-TECHNE CORP's shareholder history, click here.